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There are known knowns; these are things we know we know.
We also know there are known unknowns; that is to say we
know there are some things we do not know.
But there are also unknown unknowns - the ones we don’t
know we don’t know.
DonaldRumsfeld,FormerU.S.SecretaryofDefense,2/12/2002
While the phrasing of this tripartite classiﬁcation was not
intended to describe the current state of natural products
research, it could have been, as it provides an apt description of
the ﬁeld today. The organic molecules lumped under the term
natural products elude an easy deﬁnition. They are a structurally
diverse collection of molecules produced by organisms in an
idiosyncratic fashion, and their biological activities reﬂect the
diversity of their producers and structures. Inclusion in or exclusion
fromthenaturalproductfamilyreﬂectstheelasticityofclassiﬁcation.
Consider three molecules that are closely related structurally and
biosynthetically: tryptophan, serotonin, and psilocin (Figure 1a).
Tryptophan’s universal distribution as a proteinogenic amino acid
excludes it from being a natural product. Serotonin’s widespread
distribution and well-understood biological activities result in its
classiﬁcation as a hormone or neurotransmitter, while psilocin, a
hallucinogenic relative produced by only a few New World
mushrooms, is a natural product. All natural products have one
feature in common, biosyntheses by a genetically encoded pathway,
and the possibilities for re-engineering these pathways connects
natural products to synthetic biology.
The opening quotation’s classiﬁcation would diﬀerentiate
natural products into the known knowns, such as the antibiotic
erythromycin, for which we know the molecule (and in this case
its genetically encoded biosynthetic pathway); the known
unknowns or “cryptic metabolites”, which have never been
isolated and characterized but whose existence can be inferred
from biosynthetic pathways in sequenced genomes; and the
unknown unknowns, or molecules whose existence has not been
suspected through genomic or any other sort of analysis.
We do not know how many natural products exist, but the
Dictionary of Natural Products lists 170,000 known structures,
which eﬀectively represents today’s universe of known knowns.
The biosynthetic pathways for most of these have not been
deﬁnitively described, but progress on this front is extremely
rapid, especially for molecules with signiﬁcant biological activity
produced by bacteria and fungi. The biosynthetic pathway
encoding the genes that synthesize erythromycin’s core, a
molecule called erythronolide, condenses seven three-carbon
fragments with additional possible transformations following
each condensation, and because of the modular and repetitive
natureofthebiosyntheticchemistry, thegeneclusterisalsolarge
(∼50 kb) and highly repetitive (Figure 1b).
1,2 Biosynthetic gene
clusters like the one making erythromycin are relatively easy to
identify in sequenced genomes, and their identiﬁcation has been
automated withprograms likeantiSMASH.
3The genesformany
biosynthetic pathways can be manipulated relatively easily to
create what have been called unnatural natural products.
4,5 The
erythromycin pathway is arguably the world’s best studied and
most manipulated natural product biosynthetic pathway, andthe
Dictionary of Natural Products describes 34 biosynthetic relatives,
some naturally occurring and some laboratory generated.
■ KNOWN KNOWNS
One important way synthetic biology connects with natural
products of the known known variety is increasing the
production of high-value materials with re-engineered pathways.
The production of artemisinic acid, a key intermediate in the
production of the important antimalarial drug artemisinin,
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Figure 1. (a) Three molecules with similar structures and largely
shared biosynthetic pathways, only one of which is a natural product.
(b) Erythronolide A, the core of the antibiotic erythromycin, which is
madebyrepetitivecondensationofthreecarbonunitsasillustratedbythe
blue and red color scheme. (c) Artemisinin, the potent antimalarial drug,
can be chemically synthesized from artemisinic acid, which can be made
onatonscalefromare-engineeredbiosyntheticpathway.(d)Coelichelin,
acrypticmetabolitefromS.coelicolor,thatwasidentiﬁedbioinformatically
and discovered with diﬀerential metabolomics. (e) Tropodithietic acid
and roseobacticide A, a structurally unusual antibiotic and an algaecide,
produced by P. gallaeciensis.
Viewpoint
pubs.acs.org/synthbio
© 2014 American Chemical Society 745 dx.doi.org/10.1021/sb400025p | ACS Synth. Biol. 2014, 3, 745−747
Terms of Userepresents a milestone achievement in this area (Figure 1c). For
the past few thousand years artemisinin, an ingredient in
traditional Chinese medicine, was obtained from the sweet
wormwood plant (Artemisia annua), and today China, Vietnam,
and East Africa are the major producers. The vagaries of
agricultural production coupled with the sensitivity of malaria
therapeutics to cost of goods considerations led Jay Keasling and
co-workers to apply synthetic biology principles to artemisinin
production.
6,7 The biosynthetic pathway leading to artemisinic
acid,whichcanbeconvertedtoartemisinininastraightforwardif
technically challenging synthetic step, was re-engineered in both
a bacterial (Eschericia coli) and a yeast (Saccharomyces cerevisiae)
host. Signiﬁcantly, the approach diﬀered from traditional
heterologous expression by using hosts belonging to diﬀerent
taxonomic kingdoms from the original plant producer, and all of
the biosynthetic steps in the pathway were recreated using genes
from a variety of organisms. The resulting pathway diﬀered from
theknownpathwayinsigniﬁcantfeatures.Forexample,theE.coli
pathway did not use the bacteria’s native deoxyxylulose-5-
phosphate (DXP) mevalonate biosynthetic pathway but instead
used the mevalonate pathway from yeast, and the enzymes were
linkedintoapolyproteinratherthanleftasfree-standing entities.
The authors reported their initial success in 2006, and after a
prolonged development period, Sanoﬁ-Aventis just announced
that it had produced 39 metric tons of artemisinic acid.
8
■ KNOWN UNKNOWNS
Saccharopolyspora erythraea, the erythromycin producer, pro-
vides a convenient example of the known unknowns or cryptic
metabolites category of natural products. The complete genome
of S. erythraea became available in 2007 and contained some 17
other pathways that were likely to produce small molecules.
9
These pathways were easily identiﬁed because of their size and
repetitive nature. The ratio of known to cryptic metabolites from
S. erythraea has been mirrored in virtually all other bacterial
genomes, and cryptic metabolites represent both a signiﬁcant
opportunityandavexingchallengefornaturalproductsresearch.
The opportunity for ﬁnding molecules with the potential utility
of erythromycin in easily cultivated producers is tantalizing, but
developing a broadly applicable approach to producing and
identifyingthemhas beenquitediﬃcult. Greg Challisandhisco-
workers pioneered one of the most successful and widely used
approachesintheirstudiesofStreptomycescoelicolor,theﬁrstfully
sequenced member of the bacterial group that has produced the
majority of useful therapeutic agents. The researchers ﬁrst
identiﬁed a cluster for a cryptic metabolite, named it coelichelin,
and proposed a structure that could guide the search.
10 They
then genetically disabled the candidate pathway and compared
the suites of small molecules, the metabolomes, of wild type and
mutant to identify a molecule present in wild type but absent in
the mutant (Figure 1d).
11 While this ad hoc approach of
generating targeted mutants and comparing metabolomes has
been successful in many other projects, a universally applicable,
high-throughput approach would greatly increase discovery
rates. One tempting strategy, moving the pathways for cryptic
metabolites to alternative hosts, has not been widely successful.
Synthetic biology might provide a more fruitful approach by
‘refactoring’ the biosynthetic pathways of cryptic metabolites. In
refactoring, which represents an even more thorough bottom-up
re-engineering than the initial artemisinin pathways developed
by the Keasling team, all noncoding DNA, regulatory proteins,
and nonessential genes are deleted from the pathway.
12 The
remaining genes are recoded to generate a DNA sequence that
diverges as much as possible from that of the native pathway.
These new genes are organized into operons and placed under
the control of synthetic promoters, terminators, and ribosome
bindingsitestocreateapathwaywithcompletelydeﬁnedgenetic
parts that shares minimal DNA sequence similarity to the native
pathway. Refactored pathways have been created for known
knowns, which represent an important proof of principle, but
success with known unknowns has not yet been reported.
■ UNKNOWN UNKNOWNS
With known knowns like artemisinin, synthetic biology supports
natural products by improving supply; with known unknowns
like cryptic metabolites, synthetic biology will likely support
natural products by enabling discovery; and with unknown
unknowns, natural products can inform synthetic biology. The
discovery of unexpected natural products from new sources with
new phenotypic screens will provide new tools for synthetic
biology. As a modest example, consider tropodithietic acid and
roseobacticide A, metabolites from marine proteobacteria that
playkeyrolesinavariablesymbiosisbetweenamarinemicroalga
(Emiliania huxleyi) and the bacterial producer (Phaeobacter
gallaeciensis)(Figure 1e).
13,14Tropodithietic acidfunctionsasan
antibioticforthesymbioticpairduringthemutualistphaseofthe
association, and roseobacticide A functions as an algal toxin
during the antagonistic phase of the association. Both represent
strikingly diﬀerent chemotypes with largely unknown gene
clusters and completely unknown biosynthetic pathways.
However, when their biosynthetic pathways are known, they
will provide powerful search tools for additional examples of
these interesting if unfamiliar structures along with new tools,
their biosynthetic enzymes, for the synthetic biology toolbox.
In the ways brieﬂy outlined in this essay, one of the most
venerable ﬁelds of chemistry, natural products, and one of the
most exciting new ﬁelds, synthetic biology, can intersect to the
mutual beneﬁt of both.
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